Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model

BACKGROUND: Despite the numerous applications of monoclonal antibodies (mAbs) in cancer therapeutics, animal models available to test the therapeutic efficacy of new mAbs are limited. NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ (NSG) mice are one of the most highly immunodeficient strains and are universal...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Jing, Wang, Lan, Ren, Jie, Kranz, Emiko, Chen, Shilin, Wu, Di, Kanazawa, Toshio, Chen, Irvin, Lu, Yunfeng, Kamata, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888328/
https://www.ncbi.nlm.nih.gov/pubmed/33593826
http://dx.doi.org/10.1136/jitc-2020-001524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888328/
https://www.ncbi.nlm.nih.gov/pubmed/33593826
http://dx.doi.org/10.1136/jitc-2020-001524

Ejemplares similares